GeNeuro SA
GNRO
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,021.90 | 60.20 | 0.76% |
| CAC 40 | 7,285.86 | 44.11 | -0.60% |
| DAX 40 | 21,205.86 | 105.16 | -0.49% |
| Dow JONES (US) | 39,142.23 | 527.16 | -1.33% |
| FTSE 100 | 8,275.66 | 0.06 | 0.00% |
| HKSE | 21,395.14 | 338.16 | 1.61% |
| NASDAQ | 16,286.45 | 20.71 | -0.13% |
| Nikkei 225 | 34,627.11 | 249.51 | 0.73% |
| NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
| S&P 500 | 5,282.70 | 7.00 | 0.13% |
| S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
| SSE Composite Index | 3,280.34 | 4.34 | 0.13% |